Cellid셀리드
299660 · KOSDAQ · ₩299660 · 셀리드
₩2,040▼ ₩85 (4.00%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩8.8B | ₩4.2B | — | ₩480M | ₩909M |
| Cost of sales | ₩7.3B | ₩3.5B | — | ₩325M | ₩0 |
| Gross profit | ₩1.6B | ₩705M | — | ₩155M | ₩909M |
| Operating income | −₩11B | −₩12B | −₩12B | −₩15B | −₩13B |
| Net income | −₩12B | −₩12B | −₩12B | −₩23B | −₩13B |
| Net income to shareholders | −₩12B | −₩12B | −₩12B | −₩23B | −₩13B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩111B | ₩76B | ₩64B | ₩46B | ₩58B |
| Current assets | ₩24B | ₩11B | ₩17B | ₩21B | ₩21B |
| Cash and equivalents | ₩22B | ₩9B | ₩13B | ₩8.3B | ₩5.2B |
| Total liabilities | ₩37B | ₩25B | ₩23B | ₩23B | ₩19B |
| Current liabilities | ₩29B | ₩4.9B | ₩10B | ₩21B | ₩1.8B |
| Borrowings | ₩28B | ₩13B | ₩12B | ₩12B | ₩16B |
| Total equity | ₩74B | ₩51B | ₩40B | ₩22B | ₩39B |
| Shareholders' equity | ₩74B | ₩51B | ₩40B | ₩22B | ₩39B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩10B | −₩10B | −₩7.1B | −₩12B | −₩8.2B |
| Capital spending | ₩13B | ₩5.9B | ₩6.9B | ₩1.2B | ₩3.1B |
| Free cash flow | −₩23B | −₩16B | −₩14B | −₩13B | −₩11B |
Consolidated where available. Amounts in won.
Also known as: Cellid / 셀리드 / 299660 / KRX:299660
Source: KRX statistical information